Phase 3 Study of Uproleselan for R/R AML to Continue to Final OS Events Trigger
The independent Data Monitoring Committee recommends the phase 3 study evaluating treatment with uproleselan in patients with relapsed/refractory acute myeloid leukemia to continue to the original planned final overall survival events trigger.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- Management of Acute Myeloid Leukemia: A Review
- Treatment of Acute Myeloid Leukaemia
- Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates
- Research blog: Accelerating progress in AML
- Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012